NovaBridge Biosciences

NovaBridge Biosciences is a clinical-stage biotechnology company specializing in the development of novel biologics targeting cancers and autoimmune disorders. Its core function is to accelerate the translation of breakthrough medicines from discovery to clinical application, with a strategic emphasis on immuno-oncology and immuno-inflammation therapies. Notably, the company employs a hub-and-spoke business model, connecting Asian biotech innovations with global markets and managing risk through specialized subsidiaries focused on distinct therapeutic areas. Major clinical assets include Givastomig—a bispecific antibody advancing in global trials for gastric cancer—and VIS-101, a bifunctional biologic for ocular diseases, each representing substantial advancement for unmet patient needs. NovaBridge actively pursues efficient capital deployment and rapid proof-of-concept development, seeking business growth via strategic partnerships, licensing agreements, and spin-offs. Through its recent rebranding and dual listing on leading global exchanges, NovaBridge Biosciences plays a dynamic role in expanding patient access and accelerating innovation within the biotech landscape.